The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
(1S,2R)-5'-methoxy-2-(3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one ID: ALA4467348
PubChem CID: 58486335
Max Phase: Preclinical
Molecular Formula: C28H28N6O2
Molecular Weight: 480.57
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COc1ccc2c(c1)[C@@]1(C[C@@H]1c1ccc3c(-c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2
Standard InChI: InChI=1S/C28H28N6O2/c1-33-9-11-34(12-10-33)25-8-4-18(16-29-25)26-20-6-3-17(13-24(20)31-32-26)22-15-28(22)21-14-19(36-2)5-7-23(21)30-27(28)35/h3-8,13-14,16,22H,9-12,15H2,1-2H3,(H,30,35)(H,31,32)/t22-,28-/m1/s1
Standard InChI Key: JAHZZERYOWPURL-SKCUWOTOSA-N
Molfile:
RDKit 2D
36 42 0 0 0 0 0 0 0 0999 V2000
17.2761 -22.5985 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4878 -22.3880 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.6996 -23.1759 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.7421 -22.7162 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.2035 -22.1033 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.6158 -21.3988 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.4187 -21.5788 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9741 -20.9742 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.7277 -20.1894 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.9209 -20.0126 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.3691 -20.6185 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.5637 -23.5137 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.9982 -22.2160 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.6875 -22.6525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.7421 -21.0190 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.0233 -21.4033 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.4394 -21.4531 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.4116 -22.2728 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.1826 -22.5525 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
20.6869 -21.9057 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
20.2275 -21.2263 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.4913 -20.4560 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.2941 -20.2976 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.5569 -19.5246 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
21.0178 -18.9093 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.2127 -19.0721 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.9537 -19.8450 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.2801 -18.1389 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.0827 -17.9801 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.3450 -17.2100 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.8083 -16.5933 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
21.0057 -16.7520 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.7399 -17.5275 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.2774 -19.5905 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.0312 -18.8113 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.0729 -15.8201 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
1 3 1 0
2 4 1 0
2 7 1 1
6 5 1 0
5 4 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 10 1 0
10 11 2 0
11 6 1 0
4 12 2 0
1 13 1 1
13 14 2 0
14 18 1 0
17 15 1 0
15 16 2 0
16 13 1 0
17 18 2 0
18 19 1 0
19 20 1 0
20 21 2 0
21 17 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 26 1 0
26 27 2 0
27 22 1 0
21 22 1 0
28 29 1 0
28 33 1 0
29 30 1 0
30 31 1 0
31 32 1 0
32 33 1 0
25 28 1 0
34 35 1 0
9 34 1 0
31 36 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 480.57Molecular Weight (Monoisotopic): 480.2274AlogP: 3.76#Rotatable Bonds: 4Polar Surface Area: 86.38Molecular Species: NEUTRALHBA: 6HBD: 2#RO5 Violations: ┄HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 13.38CX Basic pKa: 7.45CX LogP: 3.66CX LogD: 3.33Aromatic Rings: 4Heavy Atoms: 36QED Weighted: 0.46Np Likeness Score: -0.62
References 1. Li SW, Liu Y, Sampson PB, Patel NK, Forrest BT, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Hodgson R, Beletskaya I, Mao G, Mason JM, Wei X, Luo X, Kiarash R, Green E, Mak TW, Pan G, Pauls HW.. (2016) Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy., 26 (19): [PMID:27592744 ] [10.1016/j.bmcl.2016.08.063 ]